Crossmark

MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway

Crossref DOI link: https://doi.org/10.1186/s13062-019-0241-1

Published Online: 2019-05-03

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rao, Mei

Chen, Dongfeng

Zhan, Peng

Jiang, Jianqing
License Information

Text and Data Mining valid from 2019-05-03
More Information

Article History

Received: 23 October 2018

Accepted: 21 April 2019

First Online: 3 May 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.